RGEN:NSD-Repligen Corporation (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 146.95

Change

+1.30 (+0.89)%

Market Cap

USD 8.36B

Volume

0.18M

Analyst Target

USD 161.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

+9.80 (+1.86%)

USD 192.19B
COO The Cooper Companies, Inc. Com..

+0.29 (+0.31%)

USD 18.65B
ALGN Align Technology Inc

+5.93 (+2.86%)

USD 17.86B
HOLX Hologic Inc

+0.18 (+0.25%)

USD 17.14B
MMSI Merit Medical Systems Inc

+0.47 (+0.48%)

USD 6.15B
ICUI ICU Medical Inc

+2.19 (+1.42%)

USD 3.97B
XRAY Dentsply Sirona Inc

-0.05 (-0.26%)

USD 3.92B
LMAT LeMaitre Vascular Inc

+1.25 (+1.37%)

USD 2.27B
AZTA Azenta Inc

+0.22 (+0.44%)

USD 2.08B
ATRC AtriCure Inc

-0.01 (-0.03%)

USD 1.67B

ETFs Containing RGEN

FBT:LSE First Trust Global Funds .. 3.67 % 0.00 %

+8.20 (+0.79%)

USD 8.11M
FBTU:LSE First Trust Global Funds .. 3.67 % 0.00 %

+0.16 (+0.79%)

USD 8.11M
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

+0.16 (+0.79%)

CAD 0.01B
FRTY Alger Mid Cap 40 ETF 0.00 % 0.00 %

+0.14 (+0.79%)

USD 0.07B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.27% 52% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.27% 52% F 33% F
Trailing 12 Months  
Capital Gain -19.97% 50% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.97% 50% F 32% F
Trailing 5 Years  
Capital Gain 57.99% 78% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.99% 78% C+ 74% C
Average Annual (5 Year Horizon)  
Capital Gain 11.94% 56% F 64% D
Dividend Return 11.94% 56% F 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.17% 63% D 44% F
Risk Adjusted Return 27.65% 77% C+ 60% D-
Market Capitalization 8.36B 89% A- 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.